Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $64M | $11M | $8M | $11M | 17.4% | 17.0% | 46.3% |
| 2024 | $55M | $7M | $5M | $9M | 11.6% | 13.8% | 62.7% |
| 2023 | $48M | $5M | $3M | $-0M | 8.4% | 15.4% | 37.4% |
| 2022 | $42M | $4M | $2M | $-2M | 6.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 41.66 | 48.07 | 54.72 | 64 |
| Cost Of Revenue | 10.22 | 11.55 | 12.99 | 14.03 |
| Gross Profit | 31.44 | 36.52 | 41.73 | 49.97 |
| Operating Expense | 28.47 | 32.51 | 35.15 | 40.31 |
| Operating Income | 2.97 | 4.01 | 6.58 | 9.66 |
| EBITDA | 3.60 | 4.62 | 7.42 | 10.83 |
| EBIT | 2.97 | 4.01 | 6.58 | 9.66 |
| Pretax Income | 3 | 4.09 | 7.04 | 10.28 |
| Tax Provision | 0.69 | 0.92 | 1.89 | 2.75 |
| Net Income | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income Common Stockholders | 2.31 | 3.17 | 5.15 | 7.54 |
| Total Expenses | 38.69 | 44.06 | 48.13 | 54.34 |
| Interest Income | 0.03 | 0.08 | 0.46 | 0.62 |
| Research And Development | 1.36 | 0.92 | 0.66 | 1 |
| Selling General And Administration | 27.11 | 31.59 | 34.49 | 39.31 |
| Normalized EBITDA | 3.60 | 4.62 | 7.42 | 10.83 |
| Normalized Income | 2.31 | 3.17 | 5.15 | 7.54 |
| Basic EPS | 0.27 | 0.37 | 0.60 | 0.89 |
| Diluted EPS | 0.26 | 0.36 | 0.58 | 0.85 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.23 | 0.23 | 0.27 | 0.27 |
| Net Income From Continuing Operation Net Minority Interest | 2.31 | 3.17 | 5.15 | 7.54 |
| Reconciled Depreciation | 0.63 | 0.61 | 0.84 | 1.17 |
| Reconciled Cost Of Revenue | 10.22 | 11.55 | 12.99 | 14.03 |
| Net Interest Income | 0.03 | 0.08 | 0.46 | 0.62 |
| Net Income From Continuing And Discontinued Operation | 2.31 | 3.17 | 5.15 | 7.54 |
| Total Operating Income As Reported | 2.97 | 4.01 | 6.58 | 9.66 |
| Diluted Average Shares | 8.77 | 8.70 | 8.86 | 8.91 |
| Basic Average Shares | 8.47 | 8.46 | 8.56 | 8.45 |
| Diluted NI Availto Com Stockholders | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income Including Noncontrolling Interests | 2.31 | 3.17 | 5.15 | 7.54 |
| Net Income Continuous Operations | 2.31 | 3.17 | 5.15 | 7.54 |
| Other Income Expense | 0 | 0 | 0 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.03 | 0.08 | 0.46 | 0.62 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.03 | 0.08 | 0.46 | 0.62 |
| Operating Revenue | 41.66 | 48.07 | 54.72 | 64 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Electromed, Inc.this co. | ELMD | $208M | 24.37β premium | 4.57 | 17.4% | 15.06 |
| Keros Therapeutics, Inc. | KROS | $220M | 4.83 | 0.72 | 28.7% | -0.72 |
| Sight Sciences, Inc. | SGHT | $216M | - | 3.32 | -60.1% | -4.83 |
| LifeMD, Inc. | LFMD | $210M | - | 8.93 | 62.0% | -27.13 |
| Utah Medical Products, Inc. | UTMD | $207M | 19.24 |
| 1.74 |
| 9.5% |
| 7.91 |
| OraSure Technologies, Inc. | OSUR | $205M | - | 0.61 | -20.2% | -0.32 |
| Atrium Therapeutics, Inc. | RNA | $202M | - | -3.21 | -37.0% | - |
| OmniAb, Inc. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| Replimune Group, Inc. | REPL | $197M | - | 0.90 | -59.5% | -0.01 |
| Peer Median | - | 12.03 | 0.82 | -22.2% | -0.72 | |